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Introduction: We evaluated HIV drug resistance in adults who
received early vs. delayed antiretroviral therapy (ART) in a multina-
tional trial [HIV Prevention Trials Network (HPTN) 052, enrollment
2005–2010]. In HPTN 052, 1763 index participants were random-
ized to start ART at a CD4 cell count of 350–550 cells/mm3 (early
ART arm) or ,250 cells/mm3 (delayed ART arm). In May 2011,
interim study results showed benefit of early ART, and all partic-
ipants were offered ART regardless of CD4 cell count; the study
ended in 2015.
Received for publication September 11, 2017; accepted December 18, 2017.
From the *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Vaccine and Infectious Disease Division, Fred Hutchinson Cancer
Research Center, Seattle, WA; ‡Frontier Science and Technology Research Foundation, Amherst, NY; §Specialty Molecular Division, Lancet Laboratories and
BARC-SA, Johannesburg, South Africa; kHIV Pathogenesis Research Unit, Faculty of Health Sciences, University of theWitwatersrand, Johannesburg, South Africa;
¶Laboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute, Rio de Janeiro, Brazil; #Y. R. Gaitonde Centre for AIDS Research and Education,
Chennai, India; **National Institute for Research in Tuberculosis, Chennai, India; ††Department of Medicine, University of North Carolina at Chapel Hill, Chapel
Hill, NC; ‡‡Department of Specialty Services, Southwest CARE Center, Santa Fe, NM; §§HPTN Leadership and Operations Center, FHI 360, Washington, DC;
kkHPTN Leadership and Operations Center, FHI 360, Durham, NC; ¶¶Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC;
##UNC Project-Malawi, Institute for Global Health and Infectious Diseases, Lilongwe, Malawi; ***CART CRS, YRGCARE Medical Centre, VHS, Chennai, India;
†††Department of Medicine, University of Zimbabwe, Harare, Zimbabwe; ‡‡‡Hospital Geral de Nova Iguacu and Laboratorio de AIDS e Imunologia Molecular-
IOC/Fiocruz, Rio de Janeiro, Brazil §§§College of Medicine-Johns Hopkins Project, Blantyre, Malawi; kkkKenya Medical Research Institute (KEMRI)-Centers for
Disease Control (CDC), Kisumu, Kenya; ¶¶¶Department of Epidemiology and Biostatistics, National AIDS Research Institute (ICMR), Pune, India; ###Department
of Infectious Diseases, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil; ****Instituto Nacional de Infectologia Evandro Chagas-INI-Fiocruz, Rio de
Janeiro, Brazil; ††††Perinatal HIV Research Unit, University of the Witwatersrand, Soweto HPTN CRS, Soweto, South Africa; ‡‡‡‡Research Institute for Health
Sciences, Chiang Mai University, Chiang Mai, Thailand; §§§§Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana; and kkkkClinical HIV Research
Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Supported by grants from the Division of AIDS of the U.S. National Institute of Allergy and Infectious Diseases (NIAID); and by the Office of AIDS Research of
the U.S. National Institutes of Health (NIH) [UM1-AI068613 (S.H.E); UM1-AI068617 (Donnell); and UM1-AI068619 (El-Sadr)]. Study drugs used in
HPTN 052 were donated by Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithK-
line/ViiV Healthcare, and Merck & Co., Inc.
C.W. served as a consultant for Celera for development of software updates related to the HIV drug resistance algorithm used with the ViroSeq HIV-1 Genotyping
System. J.J.E. receives honoraria for advisory board membership from Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., and ViiV
Healthcare and research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., Sangamo BioSciences, and ViiV
Healthcare through contracts to the University of North Carolina. J.E.G. receives honoraria for advisory board membership from Bristol-Myers Squibb, Gilead
Sciences, Theratechnologies, Merck & Co., and ViiV Healthcare. JEG’s organization receives research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences,
Janssen Therapeutics, Merck & Co., Sangamo BioSciences, and ViiV Healthcare. M.C.H. has received honoraria for advisory board membership from ViiV
healthcare. M.S.C. receives honoraria for advisory board membership from Janssen Global Services, Roche Molecular Systems, and Merck Research. S.H.E. has
collaborated with investigators from Abbott Diagnostics on research studies. For the remaining authors have no funding or conflicts of interest to disclose.
Author contributions are moved to Acknowledgments section.
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). Boehringer Ingelheim
Pharmaceuticals, Inc. (BIPI) had no role in the design, analysis or interpretation of the results in this study; BIPI was given the opportunity to review the
manuscript for medical and scientific accuracy as it relates to BIPI substances, as well as intellectual property considerations.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this
article on the journal’s Web site (www.jaids.com).
Correspondence to: Susan H. Eshleman, MD, PhD, Department of Pathology, The Johns Hopkins Medical Institutions, Ross Building, Room 646, 720 Rutland
Avenue, Baltimore, MD 21205 (e-mail: seshlem@jhmi.edu). 
participants not already on ART were offered ART regardless of
CD4 cell count and were informed of the benefits of early ART.
The study continued until May 2015. In the delayed ART arm,
96% of the index participants had initiated ART by the end of
the study.2 The overall reduction in HIV transmission in the
early ART arm compared with the delayed ART arm was 93%.2
We previously analyzed virologic outcomes in the
HPTN 052 study.18,19 In the first phase of the study (by
May 2011), participants in the delayed ART arm took longer
to achieve viral suppression compared with those in the early
ART arm.18 Over the entire trial period, higher pre-ART viral
load was associated with a longer time to viral suppression,
but was not associated with increased risk of virologic
failure.19 In the first phase of the study, the frequency of
HIV drug resistance at the time of virologic failure differed by
study arm. That study included resistance data from only 8
participants from the delayed ART arm because most
participants in the delayed ART arm did not start ART until
after May 2011.13 A preliminary comparison of drug
resistance in the 2 study arms in that study found a higher
rate of resistance in the delayed ART arm compared with the
early ART arm [7/8 (87.5%) vs. 30/85 (35.3%), P = 0.006].13
In this report, we extended the analysis of HIV drug
resistance in the HPTN 052 trial to include participants who
failed ART at any time during the trial (through May 2015).
This increased the number of participants analyzed in both
study arms, which provided more power for identifying
factors associated with emergence of resistance. Inclusion
of participants from the entire trial period also allowed us to
compare drug resistance among participants in the early ART
arm to those in the delayed ART arm who started ART before
vs. after release of the interim study results. These 2 groups
started ART at different baseline CD4 cell counts and had
different knowledge about the benefits of early ART.
METHODS
Samples Used for Analysis
HPTN 052 enrolled 1763 HIV serodiscordant couples
at 13 sites in 9 countries [Botswana, Brazil, India, Kenya,
Malawi, South Africa, Thailand, United States of America,
and Zimbabwe] (NCT00074581).1,2 HIV-infected index
participants reported being ARV-naive; previous short-term
ARV drug use for prevention of mother-to-child transmission
(PMTCT) was allowed. This report includes analysis of
samples collected before ART initiation (baseline) and at
the time of virologic failure. Baseline samples used for
genotyping were collected at the enrollment visit in the early
ART arm and near the time of ART initiation in the delayed
ART arm (range: 1–83 days before ART initiation). After
ART initiation, viral load testing was performed at quarterly
visits; participants enrolled after November 2006 also had
viral load testing 1 month after ART initiation. Virologic
failure was defined as having 2 consecutive HIV viral loads
.1000 copies/mL more than 24 weeks after ART initiation.
Failure samples used for genotyping were collected at 1 of
these 2 study visits. Index participants were excluded from
analysis if their baseline HIV viral load was#400 copies/mL.
Methods: Virologic failure was defined as 2 consecutive viral loads 
.1000 copies/mL .24 weeks after ART initiation. Drug resistance 
testing was performed for pretreatment (baseline) and failure samples 
from participants with virologic failure.
Results: HIV genotyping results were obtained for 211/249 
participants (128 early ART arm and 83 delayed ART arm) with 
virologic failure. Drug resistance was detected in 4.7% of partic-
ipants at baseline; 35.5% had new resistance at failure. In univariate 
analysis, the frequency of new resistance at failure was lower among 
participants in the early ART arm (compared with delayed ART arm, 
P = 0.06; compared with delayed ART arm with ART initiation 
before May 2011, P = 0.032). In multivariate analysis, higher 
baseline viral load (P = 0.0008) and ART regimen (efavirenz/
lamivudine/zidovudine compared with other regimens, P = 0.024) 
were independently associated with higher risk of new resistance 
at failure.
Conclusions: In HPTN 052, the frequency of new drug resistance 
at virologic failure was lower in adults with early ART initiation. 
The main factor associated with reduced drug resistance with early 
ART was lower baseline viral load.
Key Words: HIV, HPTN 052, early ART, virologic failure, 
resistance
(J Acquir Immune Defic Syndr 2018;77:484–491)
INTRODUCTION
Initiation of antiretroviral therapy (ART) at higher CD4 
cell counts decreases HIV transmission1,2 and improves out-
comes and quality of life for those on treatment.3–7 Although 
there are clear individual and public health benefits to early ART 
initiation, emergence of HIV drug resistance remains a concern 
in both HIV prevention and treatment settings. Drug-resistant 
HIV may emerge during treatment and can be transmitted to 
others, limiting future treatment options. HIV drug resistance is 
frequently observed at the time of ART failure.8–12 Several 
factors have been associated with drug resistance at failure, 
including the presence of resistance before treatment, previous 
exposure to antiretroviral (ARV) drugs, higher baseline viral 
load, lower baseline CD4 cell count (,50 cells/mm3), low 
adherence to ART, younger age in women, and having no 
education/schooling.13–15 Some studies suggest that individuals 
who initiate ART at higher CD4 cell counts (.350 cells/mm3) 
may be less likely to have drug resistance at failure.13,16,17
The multinational HIV Prevention Trials Network 
(HPTN) 052 study evaluated the impact of early ART on HIV 
transmission in serodiscordant couples.1,2 HIV-infected index 
participants were enrolled with CD4 cell counts of 350–550 
cells/mm3 (enrollment period 2005–2010). Couples were ran-
domized to 1 of 2 study  arms. In the early ART arm, index  
participants started ART at study enrollment. In the delayed 
ART arm, index participants started ART once their CD4 cell 
count dropped below 250 cells/mm3 or they developed an 
AIDS-defining illness.1,2 In May 2011, interim study results 
revealed that early ART initiation prevented 96% of HIV 
transmissions and offered health benefits to the index partici-
pant.1 After release of the interim study results, all index
In a previous report, we demonstrated that many participants 
who had HIV viral loads #400 copies/mL at enrollment were 
using ART but did not disclose this to study staff.20
Laboratory Methods
CD4 cell count and HIV viral load were determined at 
study sites.1,2 HIV genotyping was performed at 4 study sites 
(Pune and Chennai, India; Johannesburg, South Africa; and 
Rio de Janeiro, Brazil) and at the HPTN Laboratory Center 
(Baltimore, MD, USA) using the ViroSeq HIV-1 Genotyping 
System, v2.8 (Abbott Molecular, Des Plaines, IL). Drug 
resistance results were obtained from FASTA files using the 
Resistance Calculator Program at Frontier Science Founda-
tion using the Stanford v7.0 algorithm. Phylogenetic analysis 
was performed to determine HIV subtype in the pol region 
(HIV protease and reverse transcriptase). FASTA sequences 
were aligned using MegAlign v14.0 (Clustal W method); 
alignments included 139 reference sequences representing 
different subtypes and circulating recombinant forms from the 
database of the Los Alamos National Laboratory (https://
www.hiv.lanl.gov). PHYLIP v3.695 was used to generate 
phylogenetic trees and bootstrap values. FASTA files were 
submitted to a public database (GenBank, accession numbers: 
KT833391-KT833560, KU562071-KU562073, KU562075, 
KU562077, KU562079-KU562081, KU562083, KU562085, 
MF573212-MF573297, and MF594795-MF594950).
Statistical Methods
Baseline characteristics of groups defined by study arm 
and study group were analyzed using x2, analysis of variance, 
and t tests. Univariate and multivariate associations between 
baseline factors and HIV drug resistance were analyzed using 
logistical regression.
Ethical Considerations
Institutional review boards and ethics committees at 
each participating institution approved the HPTN 052 study. 
Written informed consent was obtained from all study 
participants for participation in the HPTN 052 study.
RESULTS
Study Cohort
In HPTN 052, 249 of 1671 participants who initiated 
ART during the study met the criteria for virologic failure; 38 
(15%) of the 249 participants were excluded from analysis 
(12 had viral loads #400 copies/mL at ART initiation, 15 did 
not have paired baseline/failure samples available for resis-
tance testing, and 11 did not have paired resistance results 
because of genotyping failure). Resistance results were 
obtained from paired baseline/failure samples for 211 partic-
ipants with virologic failure, including 128 participants in the 
early ART arm and 83 participants in the delayed ART arm. 
The 83 participants in the delayed ART arm included 22 who 
started ART before May 2011 and 61 who started ART after 
May 2011 (Table 1).
Table 1 shows characteristics of participants included in 
this report. By design, the median [interquartile range (IQR)] 
baseline CD4 cell count was significantly higher in the early 
ART arm compared with the delayed ART arm [454 (373–535) 
cells/mm3 vs. 311 (236–415) cells/mm3, P , 0.001]. Baseline 
CD4 cell count was also higher in the delayed ART arm among 
those who initiated ART after May 2011 (when ART was 
offered to all  index participants regardless of CD4 cell count) 
than among those who initiated ART before May 2011. Median 
(IQR) baseline HIV viral load was significantly lower in the early 
ART arm compared with the delayed ART arm [4.5 (3.8–5.0) 
log10 copies/mL vs. 4.9 (4.4–5.3) log10 copies/mL, P , 0.001]; 
median (IQR) baseline viral load was also significantly lower in 
the early ART arm compared with the subgroup in the delayed 
arm who started ART before May 2011 [4.5 (3.8–5.0) log10 
copies/mL vs. 5.2 (4.3–5.5) log10 copies/mL, P = 0.006].
HIV subtype was determined for all 211 participants. 
The most common HIV subtype was subtype C (n = 162, 
76.8%), followed by subtype B (n = 25, 11.8%). The HIV 
subtypes of the other 24 participants were: A1 (n = 7), A2 (n 
= 1), D (n = 1), F1 (n = 6), CRF01_AE (n = 4), and other 
recombinants (n = 5). Among the 211 participants, 158 
(74.9%) were taking a regimen of efavirenz (EFV), lamivu-
dine (3TC), and zidovudine (ZDV); 44 (20.9%) were taking 
protease inhibitor (PI)–based regimens (28 were taking 
atazanavir-based ART; 16 were taking lopinavir/ritonavir-
based ART), and 9 (4.3%) were taking other EFV-based 
regimens. There were no significant differences in enrollment 
region (America, Africa, and Asia), ART regimen type (EFV/ 
3TC/ZDV vs. other), educational level, marital status, or 
number of sex partners among participant groups (Table 1).
HIV Drug Resistance at Baseline
Among the 211 participants with virologic failure, 10 
(4.7%) had drug resistance at baseline (Fig. 1). Five had 
nonnucleoside reverse transcriptase inhibitor (NNRTI) resis-
tance and 5 had dual-class resistance (NNRTI resistance and 
nucleoside reverse transcriptase inhibitor [NRTI] resistance). 
PI resistance was not detected. The most common NNRTI 
resistance detected at baseline was K103N (40.0%), which 
causes high-level resistance to EFV and nevirapine. Other 
baseline NNRTI resistance mutations were Y181C and 
K101E, which also cause resistance to etravirine and 
rilpivirine. The only baseline NRTI resistance mutation 
detected was M184V, which causes high-level resistance to 
3TC and emtricitabine, with low-level resistance to abacavir 
and didanosine; this mutation also increases susceptibility to 
tenofovir and other NRTI drugs. Of the 10 participants with 
baseline resistance, 9 failed an EFV-based ART regimen and 
1 failed a PI-based ART regimen.
There was no significant difference in frequency of 
baseline drug resistance by study arm (4.7% early ART arm 
vs. 4.8% delayed ART arm, P = 0.96; Supplemental Digital 
Content 1, http://links.lww.com/QAI/B105). The frequency of 
baseline drug resistance was highest (9.1%) among the 22 
participants in the delayed ART arm who started ART before 
May 2011. None of the other factors analyzed were associated 
with baseline drug resistance (Supplemental Digital Content 1,
http://links.lww.com/QAI/B105). The failure to see associations
of baseline resistance and other factors may have reflected the
low frequency of baseline resistance in this cohort.
HIV Drug Resistance at Failure
Overall, 83 (39.3%) of the 211 participants had drug
resistance detected at failure. The 83 participants included all
10 participants who had drug resistance at baseline. Newly
acquired resistance was detected in 75 (35.5%) of the 211
participants (Fig. 1). Of those with new resistance, 47
acquired NNRTI resistance only, 16 acquired NRTI resis-
tance only, and 12 acquired dual-class resistance (NNRTI +
NRTI resistance). PI resistance was not detected. Among the
75 participants with new resistance at failure, 2 had baseline
NNRTI resistance and acquired NRTI resistance during





N = 83 P
Delayed ART
(Before 5/11), N = 22
Delayed ART (After 5/11),
N = 61 P
Median age (IQR) 31 (26–36) 33 (27–39) 0.08 33 (25–40) 33 (27–37) 0.87
Sex 0.06 0.69
Male 65 (50.8%) 31 (37.3%) 9 (40.9%) 22 (36.1%)
Female 63 (49.2%) 52 (62.7%) 13 (59.1%) 39 (63.9%)
Median CD4 cell count (IQR) 454 (373–535) 311 (236–415) ,0.001 226 (196–249) 361 (301–440) ,0.001
Median log10 viral load (IQR) 4.5 (3.8–5.0) 4.9 (4.4–5.3) ,0.001 5.2 (4.3–5.5) 4.9 (4.4–5.2) 0.58
Median time to ART initiation (IQR) 0 (0–0) 2.4 (1.7–3.2) ,0.001 1.8 (0.81–2.5) 2.5 (2.0–3.2) 0.001
Region 0.75 0.07
America 24 (18.8%) 18 (21.7%) 7 (31.8%) 11 (18.0%)
Asia 38 (29.7%) 21 (25.3%) 8 (36.4%) 13 (21.3%)
Africa 66 (51.6%) 44 (53.0%) 7 (31.8%) 37 (60.7%)
Regimen* 0.78 0.68
EFV/3TC/ZDV 95 (74.2%) 63 (75.9%) 16 (72.7%) 47 (77.0%)
Other 33 (25.8%) 20 (24.1%) 6 (27.3%) 14 (23.0%)
Education 0.39 0.29
None 22 (17.2%) 10 (12.0%) 1 (4.5%) 9 (14.8%)
Primary or secondary schooling 100 (78.1%) 71 (85.5%) 21 (95.5%) 50 (82.0%)
Postsecondary schooling 6 (4.7%) 2 (2.4%) 0 (0.0%) 2 (3.3%)
Marital status 0.17 0.55
Married 122 (95.3%) 82 (98.8%) 22 (100.0%) 60 (98.4%)
Not married 6 (4.7%) 1 (1.2%) 0 (0.0%) 1 (1.6%)
No. of sex partners† 0.55 0.45
0–1 123 (96.1%) 81 (97.6%) 21 (95.5%) 60 (98.4%)
.1 5 (3.9%) 2 (2.4%) 1 (4.5%) 1 (1.6%)
P-values ,0.05 are bolded. The x2 test was used for categorical variables. For continuous variables, t tests were used for 2-group comparisons, allowing for unequal variance;
analysis of variance was used for 3-group comparisons.
*Among the 211 participants who failed ART, 158 (74.9%) were taking EFV/3TC/ZDV, 44 (20.9%) were taking PI-based regimens (26 were taking atazanavir-based ART and 2
were taking atazanavir/ritonavir-based ART), and 9 (4.3%) were taking a different EFV-based regimen.
†Number of sex partners in the 3 months before ART initiation.
FIGURE 1. The figure shows the fre-
quency of HIV drug resistance at baseline
and new resistance at failure among
participants with virologic failure in
HPTN 052. Paired baseline and failure
HIV genotyping results were obtained for
211 participants. ART was initiated at
a CD4 cell count of 350–550 cells/mm3
(early ART arm) or ,250 cells/mm3
(delayed ART arm, before release of the
interim study report in May 2011). After
May 2011, all HIV-infected index partic-
ipants in the delayed ART arm were
offered ART regardless of CD4 cell count.
treatment. The resistance mutations detected in 71 (94.7%) of 
the 75 participants were consistent with the ARV drugs in 
their ART regimens. In the other 4 cases, participants with 
new NNRTI resistance were taking a PI-based ART regimen 
(none had baseline resistance). None of the 4 participants 
switched ART regimens before failing treatment; 1 reported 
having received a single dose of nevirapine for PMTCT 
before enrollment.
The most common NNRTI resistance mutation 
acquired during treatment was K103N [detected in 47 
(79.7%) of the 59 cases with new NNRTI resistance]. The 
most common NRTI resistance mutation acquired during 
treatment was M184V (detected in all 28 cases with new 
NRTI resistance). In 2 cases, participants acquired thymidine 
analog mutations in addition to M184V (1 acquired D67N 
and 1 acquired K219R). The NRTI resistance mutation, 
K65R, was not detected. This mutation reduces susceptibility 
to several NRTI drugs, including tenofovir and emtricitabine, 
which are used for HIV treatment and prevention. There were 
no significant differences in the types of mutations detected in 
participants in the 2 study arms, or in participants infected 
with subtype C HIV vs. other subtypes.
The frequency of new drug resistance at failure was 
lower among the 128 participants in the early ART arm than 
among the 83 participants in the delayed ART arm, but the 
difference was not statistically significant (30.5% vs. 43.4%, 
P = 0.06, Table 2 and Fig. 1). The log10 viral load at the time 
of virologic failure was similar in the 2 study arms (P = 0.19, 
data not shown); therefore, the failure to observe a difference 
in the frequency of drug resistance in the 2 arms was not due 
to low viral load (sampling error during HIV genotyping). 
The frequency of new resistance was significantly lower 
among participants in the early ART arm than among 
participants in the delayed ART arm who started ART before 
May 2011 (30.5% vs. 54.5%, P = 0.032, univariate analysis, 
Table 2 and Fig. 1). Other factors associated with new drug 
resistance at virologic failure in univariate analyses included: 
ART regimen (EFV/3TC/ZDV compared with other ART 
regimens, P = 0.0074), higher baseline viral load (P , 
0.0001), and lower baseline CD4 cell count (P = 0.047, Table 
2). In a multivariate model, 2 factors remained significantly 
associated with new drug resistance at failure: ART regimen 
(EFV/3TC/ZDV, P = 0.024) and higher baseline viral load (P 
= 0.0008, Table 2).
The median (IQR) baseline viral load was 4.98 (4.42–
5.39) log10 copies/mL among those with new resistance at 
failure and 4.48 (3.92–4.94) log10 copies/mL among those 
without new resistance (P , 0.0001). We also analyzed the 
association of ART regimen and new resistance at failure 
when all participants on EFV-based ART were grouped 
together; when participants on EFV-based ART were com-
pared with those on PI-based ART, the association between 
ART regimen and new resistance at failure was only 
significant in the univariate model (Table 2, footnote).
One factor that may have affected the results was that 
the follow-up period between ART initiation and virologic 
failure was different in the 2 study arms (early ART arm: 177 
person-years and delayed ART arm: 83 person-years). To 
address this, additional statistical analyses were performed in
which follow-up time in the early ART arm was censored at 
2.7 years (the maximum length of follow-up in the delayed 
ART arm) (Supplemental Digital Content 2, http://links.lww. 
com/QAI/B105). The additional analysis indicated that the 
different length of ART follow-up in the 2 study arms did not 
significantly affect the study findings.
The proportion of participants with new resistance at 
virologic failure was similar among those who did or did not 
achieve viral suppression before virologic failure [45/114 
(39%) vs. 30/97 (31%), P = 0.20] and was similar among 
those who did or did not achieve viral suppression in the first 
3 months after ART initiation [34/91 (37%) vs. 41/120 (34%), 
P = 0.63]. Among the 75 participants with new resistance at 
failure, only 18 (24%) were virally suppressed for 12 months 
or longer before failing ART.
DISCUSSION
This report extends our previous analysis of HIV drug 
resistance in HPTN 052 by including virologic failure events 
that occurred throughout the HPTN 052 study (through May 
2015). This increased the number of participants included in the 
analysis for both study arms (from 85 to 128 in the early ART 
arm and from 8 to 83 in the delayed ART arm), and allowed us 
to assess resistance among participants in the delayed ART arm 
who started ART before vs. after release of the interim study 
report. This report includes analysis of 211 participants with 
virologic failure. The frequency of baseline (pretreatment) 
resistance in this group was 4.7% and was similar in the 2 
study arms. Other studies have detected pretreatment resistance 
in ;5% of participants in ART-naive cohorts,8,21–25 with higher 
frequencies (.9%) among those who later failed ART.8,23 In 
HPTN 052, none of the clinical or demographic factors 
evaluated were associated with baseline drug resistance.
At virologic failure, 36% of the participants in HPTN 
052 had new resistance to at least one drug. Higher rates of 
resistance have been reported in other studies in which ART 
was initiated at lower CD4 cell counts (50%–95%).8–12,17 The 
risk of resistance increases if individuals continue to receive 
an ART regimen after virologic failure.26–29 The lower 
frequency of resistance observed in HPTN 052 compared 
with previous studies may reflect frequent viral load moni-
toring, which may have limited exposure to ART in 
participants who were not virally suppressed.1 In this study, 
4 participants (3 women and 1 man) were on a PI-based 
regimen and had new NNRTI resistance at failure; in these 
cases, the NNRTI-resistant variants may have been selected 
during previous exposure to NNRTIs in PMTCT regimens or 
undisclosed ARV drug use or may have been acquired by 
superinfection with an NNRTI-resistant HIV strain.
Our previous report, which included only 8 participants 
in the delayed ART arm, found a significant difference in the 
frequency of new resistance in the early vs. delayed ART 
arms.13 This association was not observed in the extended 
analysis in this report, which included 83 delayed ART arm 
participants. We did find that participants in the early ART 
arm were less likely to acquire resistance during treatment 
than the subset of participants in the delayed ART arm who 
initiated ART at lower CD4 cell counts, before release of 
the
TABLE 2. Factors Associated With New HIV Drug Resistance at the Time of Virologic Failure in HPTN 052
n/N (%)
New Resistance at Failure
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Study arm 0.06
Early ART arm 39/128 (30.5) Ref
Delayed ART arm 36/83 (43.4) 1.73 (0.98 to 3.10)
Study group* 0.08 0.43
Early ART arm 39/128 (30.5) Ref Ref
Delayed ART arm (before 5/2011) 12/22 (54.5) 2.74 (1.09 to 6.87) 0.032 2.11 (0.68 to 6.57) 0.20
Delayed ART arm (after 5/2011) 24/61 (39.3) 1.48 (0.78 to 2.80) 0.23 1.12 (0.55 to 2.30) 0.75
Age at ART initiation 0.94
,25 yrs 14/37 (37.8) Ref
25–39 yrs 48/136 (35.3) 0.90 (0.42 to 1.90) 0.77
$40 yrs 13/38 (34.2) 0.85 (0.33 to 2.20) 0.74
Sex 0.26
Male 38/96 (39.6) Ref
Female 37/115 (32.2) 0.72 (0.41 to 1.28)
CD4 at ART initiation† 0.81 (0.65 to 1.00) 0.047 1.00 (0.77 to 1.31) 0.98
VL at ART initiation‡ 2.54 (1.63 to 3.98) ,0.0001 2.29 (1.41 to 3.72) 0.0008
Time to ART initiation§ 1.09 (0.89 to 1.33) 0.40
HIV subtype 0.63
C 59/162 (36.4) Ref
Non-C 16/49 (32.7) 0.85 (0.43 to 1.67)
Region 0.92
America 16/42 (38.1) Ref
Asia 21/59 (35.6) 0.90 (0.40 to 2.04) 0.80
Africa 38/110 (34.5) 0.86 (0.41 to 21.79) 0.68
Regimenk 0.0074
EFV/3TC/ZDV 64/158 (40.5) 2.60 (1.25 to 5.43) 2.51 (1.13 to 5.58) 0.024
Other 11/53 (20.8) Ref
Education 0.31
None 15/32 (46.9) Ref
Primary or secondary schooling 58/171 (33.9) 0.58 (0.27 to 1.25) 0.16
Postsecondary schooling 2/8 (25.0) 0.38 (0.07 to 2.16) 0.27
Marital status 0.68
Married 72/204 (35.3) Ref
Not married 3/7 (42.9) 1.37 (0.30 to 6.31)
No. of sex partners¶ 0.24
0–1 71/204 (34.8) Ref
.1 4/7 (57.1) 2.50 (0.54 to 11.47)
Baseline resistance 0.27
Yes 2/10 (20.0) 0.44 (0.09 to 2.12)
No 73/201 (36.3) Ref
Previous PMTCT# 0.46
Yes 5/18 (27.8) Ref
No 70/193 (36.3) 1.47 (0.51 to 4.32)
P-values ,0.05 are bolded. Odds ratios (OR) were calculated using logistic regression. An OR .1 indicates a higher risk of resistance. The OR could not be estimated if any cell
was 0 for the categorical variable. Variables with a P , 0.05 were included in the multivariate regression model.
*Study groups included: early ART arm (ART initiated at enrollment), delayed ART arm with ART initiation before May 2011, and delayed ART arm with ART initiation after May 2011.
†Per CD4 cell count increment of 100 cells/mm3.
‡Per viral load increment of 1 log10 HIV RNA copies/mL.
§Per 1 year increment.
kAmong the 211 participants who failed ART, 158 (74.9%) were taking EFV/3TC/ZDV, 44 (20.9%) were taking PI-based regimens, and 9 (4.3%) were taking a different EFV-based regimen. One
participant switched ART regimens before virologic failure, and one received ARV drugs for PMTCT before enrolling in the HPTN 052 trial. The association of ART regimen with new resistance at
virologic failure was also analyzed for the 167 participants taking EFV-based ART compared with the 44 participants taking PI-based ART. In this alternate model, the association between ART regimen
and resistance was statically significant in univariate analysis (OR: 2.17, 95% CI: 1.00 to 4.68; P = 0.04), but not in multivariate analysis (OR: 1.95, 95% CI: 0.85 to 4.50, P = 0.12).
¶Number of sex partners in the 3 months before ART initiation.
#Previous PMTCT indicates those who received a regimen for PMTCT while enrolled in the study, before they started their primary ART regimen.
CI, confidence interval; N, number; OR, odds ratio; Ref, reference group; VL, viral load.
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